JP2018534265A - β−ニコチンアミドモノヌクレオチドの結晶形態 - Google Patents

β−ニコチンアミドモノヌクレオチドの結晶形態 Download PDF

Info

Publication number
JP2018534265A
JP2018534265A JP2018516685A JP2018516685A JP2018534265A JP 2018534265 A JP2018534265 A JP 2018534265A JP 2018516685 A JP2018516685 A JP 2018516685A JP 2018516685 A JP2018516685 A JP 2018516685A JP 2018534265 A JP2018534265 A JP 2018534265A
Authority
JP
Japan
Prior art keywords
compound
nmn
crystalline compound
nad
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018516685A
Other languages
English (en)
Japanese (ja)
Inventor
カール，アンドリュー
フェルナンデス，フィリップ
リビングストン，デーヴィッド，ジェイ．
Original Assignee
メトロ インターナショナル バイオテック，エルエルシー
メトロ インターナショナル バイオテック，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メトロ インターナショナル バイオテック，エルエルシー, メトロ インターナショナル バイオテック，エルエルシー filed Critical メトロ インターナショナル バイオテック，エルエルシー
Publication of JP2018534265A publication Critical patent/JP2018534265A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2018516685A 2015-10-02 2016-09-30 β−ニコチンアミドモノヌクレオチドの結晶形態 Pending JP2018534265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562236657P 2015-10-02 2015-10-02
US62/236,657 2015-10-02
PCT/US2016/054776 WO2017059249A1 (en) 2015-10-02 2016-09-30 Crystal forms of beta-nicotinamide mononucleotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020205773A Division JP2021063081A (ja) 2015-10-02 2020-12-11 β−ニコチンアミドモノヌクレオチドの結晶形態

Publications (1)

Publication Number Publication Date
JP2018534265A true JP2018534265A (ja) 2018-11-22

Family

ID=56320606

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018516685A Pending JP2018534265A (ja) 2015-10-02 2016-09-30 β−ニコチンアミドモノヌクレオチドの結晶形態
JP2020205773A Pending JP2021063081A (ja) 2015-10-02 2020-12-11 β−ニコチンアミドモノヌクレオチドの結晶形態
JP2022131443A Pending JP2022176979A (ja) 2015-10-02 2022-08-22 β－ニコチンアミドモノヌクレオチドの結晶形態
JP2024111468A Pending JP2024161353A (ja) 2015-10-02 2024-07-11 β－ニコチンアミドモノヌクレオチドの結晶形態

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020205773A Pending JP2021063081A (ja) 2015-10-02 2020-12-11 β−ニコチンアミドモノヌクレオチドの結晶形態
JP2022131443A Pending JP2022176979A (ja) 2015-10-02 2022-08-22 β－ニコチンアミドモノヌクレオチドの結晶形態
JP2024111468A Pending JP2024161353A (ja) 2015-10-02 2024-07-11 β－ニコチンアミドモノヌクレオチドの結晶形態

Country Status (14)

Country Link
US (6) US10392415B2 (enExample)
EP (2) EP3355895A4 (enExample)
JP (4) JP2018534265A (enExample)
KR (1) KR102779733B1 (enExample)
CN (1) CN108697722B (enExample)
AU (1) AU2016331918B2 (enExample)
BR (1) BR112018006243A2 (enExample)
CA (1) CA3000744C (enExample)
EA (1) EA037104B1 (enExample)
GB (1) GB2542881B (enExample)
IL (1) IL258276B (enExample)
MX (1) MX390064B (enExample)
WO (1) WO2017059249A1 (enExample)
ZA (1) ZA201802657B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021192683A1 (enExample) * 2020-03-27 2021-09-30
JPWO2021200545A1 (enExample) * 2020-03-30 2021-10-07
JP2023001064A (ja) * 2021-06-18 2023-01-04 邦泰生物工程（深▲セン▼）有限公司 ニコチンアミドモノヌクレオチド共結晶を調製する方法
JP2023001065A (ja) * 2021-06-18 2023-01-04 邦泰生物工程（深▲セン▼）有限公司 ニコチンアミドモノヌクレオチド－イソニコチノイド共結晶およびその組成物
WO2025004768A1 (ja) * 2023-06-29 2025-01-02 株式会社カネカ 結晶性複合体、及びその製造方法、並びに組成物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
US20170165283A1 (en) * 2015-12-11 2017-06-15 Bontac Bio-Engineering (Shenzhen) Co., Ltd Use of beta-nicotinamide mononucleotide in preparation of health-care products for preventing and treating arteriosclerosis and cardio-cerebrovascular diseases, and health-care product containing the same
WO2016188091A1 (zh) * 2015-12-11 2016-12-01 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物
WO2018047715A1 (ja) * 2016-09-06 2018-03-15 協和発酵バイオ株式会社 β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
CN120383644A (zh) 2016-11-11 2025-07-29 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成
AU2017367092B2 (en) 2016-11-29 2022-11-03 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US10654883B2 (en) 2018-05-15 2020-05-19 Jumpstart Fertility Pty Ltd Inorganic salts of nicotinic acid mononucleotide as anti-aging agents
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
CN109939120B (zh) * 2019-03-01 2020-01-31 北京慧宝源生物技术股份有限公司 含烟酰胺单核苷酸和罗汉果苷的组合物及其应用
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CN110658224B (zh) * 2019-10-15 2022-11-22 中国中医科学院中药研究所 一种氢核磁定量分析技术测定nmn绝对含量的方法
CN112823778B (zh) * 2019-11-21 2024-06-14 百瑞全球有限公司 毛发护理组合物及其制备方法
CN113121628A (zh) * 2019-12-30 2021-07-16 尚科生物医药（上海）有限公司 一种无定型烟酰胺单核苷酸的制备方法
FR3110836B1 (fr) * 2020-05-29 2023-06-16 Nuvamid Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
CN111588729A (zh) * 2020-06-16 2020-08-28 无锡脑镁素生物医药科技有限公司 β-烟酰胺单核苷酸在预防脱发或促进毛发生长产品中的应用
CN112538101A (zh) * 2020-08-13 2021-03-23 常州博海威医药科技股份有限公司 一种β烟酰胺单核苷酸的新晶型及其制备方法和用途
CN112076204A (zh) * 2020-09-29 2020-12-15 深圳雾件科技有限公司 一种烟酰胺单核苷酸在运动神经元修复的应用
CN114349809A (zh) * 2020-10-13 2022-04-15 华东理工大学 β-烟酰胺单核苷酸的晶型A及其制备方法
KR20230113770A9 (ko) * 2020-11-27 2024-03-25 미라이랩 바이오사이언스 인코퍼레이티드 고순도 β 니코틴아미드 모노뉴클레오티드(NMN) 및 그 제조 방법
CN112694505A (zh) * 2020-12-30 2021-04-23 音芙医药科技(上海)有限公司 一种高密度的nmn的制备方法
AU2022258448A1 (en) * 2021-04-13 2023-11-09 Animal Biosciences, Inc. Formulations of nicotinic acid derivatives and flavonoid polyphenols and uses thereof
KR20240020716A (ko) 2021-05-27 2024-02-15 메트로 인터내셔널 바이오테크 엘엘씨 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법
CN113912653B (zh) * 2021-06-04 2024-04-23 天津大学 一种提高β-烟酰胺单核苷酸结晶粉末松堆密度的方法
WO2023077503A1 (zh) * 2021-11-08 2023-05-11 邦泰生物工程(深圳)有限公司 一种提高烟酰胺单核苷酸晶体的堆密度的方法及其晶体
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
CN114214270B (zh) * 2021-12-17 2023-11-24 中国农业科学院北京畜牧兽医研究所 一种调控冷冻牛卵母细胞的发育能力的方法及其应用
CN114213486A (zh) * 2021-12-31 2022-03-22 浙江拓普药业股份有限公司 一种西兰花中烟酰胺单核苷酸的提取纯化方法
CN114540283B (zh) * 2022-01-27 2023-10-20 中国农业科学院北京畜牧兽医研究所 用于牛体外胚胎生产的高效玻璃化冷冻方法
WO2024251966A1 (en) 2023-06-07 2024-12-12 Bohan & Co As. Crystalline reduced nicotinamide mononucleotide (nmnh) and process thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201389A (en) 1962-09-24 1965-08-17 Kyowa Hakko Kogyo Kk Method for preparing ribonucleoside-5'-phosphates or their salts from ribonucleosides
US3451997A (en) 1965-11-30 1969-06-24 Kyowa Hakko Kogyo Kk Monothio-phosphate ester catalysis for preparation of ribonucleoside derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4411995A (en) 1981-09-28 1983-10-25 Massachusetts Institute Of Technology Synthesis of nicotinamide cofactors
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CN100408100C (zh) 1997-07-29 2008-08-06 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
RS51031B (sr) 2001-04-30 2010-10-31 Trommsdorff Gmbh & Co.Kg.Arzneimittel Farmaceutski aktivni estri uridina
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20040224039A1 (en) 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US8512717B2 (en) 2003-08-07 2013-08-20 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2004324323A1 (en) 2003-10-31 2006-06-15 Robarts Research Institute Methods and formulations for protecting cells, and for treating diseases and conditions by optimising the intracellular concentration of NAD
ES2663226T3 (es) 2004-06-04 2018-04-11 Washington University Procedimientos y composiciones para tratar neuropatías
WO2006094235A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP5063878B2 (ja) 2005-08-30 2012-10-31 扶桑薬品工業株式会社 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
US20080020413A1 (en) * 2006-03-29 2008-01-24 Columbia University Crystalline visfatin and methods therefor
CA2646674A1 (en) 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions
US20080318892A1 (en) 2006-04-28 2008-12-25 John Geoffrey Pickering Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
EP2124985A4 (en) * 2007-01-26 2011-06-08 Univ Washington METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
CN101497638B (zh) 2008-01-30 2012-09-26 中国科学院大连化学物理研究所 一种nad+类似物及其合成和应用
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
CN101601679B (zh) 2009-03-17 2011-08-10 中国人民解放军第二军医大学 一种烟酰胺单核苷酸的应用
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
KR20110061909A (ko) * 2009-12-02 2011-06-10 삼성전자주식회사 도펀트로 도핑된 그라펜 및 이를 이용한 소자
EP2993236A1 (en) 2010-04-15 2016-03-09 Glaxosmithkline LLC Sirtuin activators and activation assays
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent
RU2016116533A (ru) 2010-09-03 2018-11-30 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
CN103384668B (zh) 2010-09-03 2017-05-31 福马Tm有限责任公司 用于抑制nampt的化合物和组合物
CA2810049A1 (en) 2010-09-03 2012-03-08 Forma Tm, Llc Guanidine compounds and compositions for the inhibition of nampt
WO2012094343A1 (en) 2011-01-05 2012-07-12 Trilink Biotechnologies Chemically substituted thermosensitive probes and cofactors for hot start ligation
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
RU2616612C2 (ru) 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
US20140221319A1 (en) 2011-06-29 2014-08-07 Mayo Foundation For Medical Education And Research Small Molecule CD38 Inhibitors and Methods of Using Same
US9458172B2 (en) 2012-03-02 2016-10-04 Kenneth W Bair Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
ES2620668T3 (es) 2012-03-02 2017-06-29 Genentech, Inc. Derivados de amidas y sulfonamidas amido espirocíclicas
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
JP2015508784A (ja) 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド アミド−ベンジルスルホン及びスルホキシド誘導体
JP6289460B2 (ja) 2012-07-16 2018-03-07 コーネル ユニヴァーシティー 難聴を治療するためのニコチンアミドリボシド
WO2014059034A2 (en) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
CN102876759A (zh) * 2012-10-29 2013-01-16 尚科生物医药（上海）有限公司 尼克酰胺腺嘌呤二核苷酸的制备方法
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
PL2968306T3 (pl) 2013-03-15 2024-01-29 Washington University Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
US20140271355A1 (en) 2013-03-15 2014-09-18 Sabre Intellectual Property Holdings Llc Apparatus and process for focused gas phase application of biocide
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
US20160287621A1 (en) 2013-11-06 2016-10-06 President And Fellows Of Harvard College Biological production of nad precursors and analogs
US10398701B2 (en) 2013-11-12 2019-09-03 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
CN105992521A (zh) 2013-11-12 2016-10-05 奥索努特拉有限责任公司 基于特咖宁的补充剂及其使用方法
EP3068364B1 (en) 2013-11-14 2021-11-03 Metro Biotech NSW Pty Ltd Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject
CN104367587B (zh) 2013-12-06 2018-06-29 中国人民解放军第二军医大学 烟酰胺单核苷酸在制备促脑缺血后神经再生药物中的应用
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
MX2016015997A (es) 2014-06-02 2017-04-05 Glaxosmithkline Intellectual Property (No 2) Ltd Preparacion y uso de beta-d-nicotinamida ribosido cristalina.
MX2016015907A (es) 2014-06-03 2018-08-01 Sulfagenix Inc Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas.
US10485814B2 (en) 2014-06-06 2019-11-26 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
US20170326100A1 (en) 2014-12-09 2017-11-16 Amorepacific Corporation Composition for activating longevity gene
CN107428791B (zh) 2015-03-09 2024-05-28 格雷斯公司 烟酰胺核苷的结晶形式
CN104817604B (zh) 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
EP3271456A1 (en) 2015-03-18 2018-01-24 The Regents of the University of California Methods of preventing and reversing stem cell aging
CA2987986A1 (en) 2015-06-04 2016-12-08 Chromadex, Inc. Selective solvent free phosphorylation
WO2016210232A1 (en) 2015-06-25 2016-12-29 N.V. Perricone Llc Niacinamide mononucleotide formulations for skin aging
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
TW201713774A (zh) 2015-08-06 2017-04-16 Kohjin Life Sciences Co Ltd 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3001483A1 (en) 2015-10-07 2017-04-13 Joel HUIZENGA Resetting biological pathways for defending against and repairing deterioration from human aging
WO2017079195A1 (en) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
WO2017110317A1 (ja) 2015-12-21 2017-06-29 昭和電工株式会社 ニコチンアミドモノヌクレオチド誘導体、その塩、その製造方法、皮膚外用剤、化粧料、食品添加剤
EP3187180A1 (en) 2015-12-28 2017-07-05 Ludwig-Maximilians-Universität München Adenosylhomocysteinase binding substances for medical use
WO2017145151A1 (en) 2016-02-23 2017-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Process for preparation of nicotinamide riboside (nr) and cosmetic composition comprising (nr and a phosphate-binding agent
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
US10183036B2 (en) 2016-04-20 2019-01-22 ChromaDex Inc. Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
CN107922952B (zh) 2016-07-30 2021-04-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN107889504B (zh) 2016-07-30 2021-07-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN108026132B (zh) 2016-07-30 2021-08-13 邦泰生物工程(深圳)有限公司 一种烟酰胺单核苷酸的纯化方法
WO2017185549A1 (zh) 2016-07-30 2017-11-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法2
WO2018023210A1 (zh) 2016-07-30 2018-02-08 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
WO2018023209A1 (zh) 2016-07-30 2018-02-08 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
WO2018047715A1 (ja) * 2016-09-06 2018-03-15 協和発酵バイオ株式会社 β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
CN109691011B (zh) 2016-09-09 2022-06-14 日本电气株式会社 发送装置、接收装置、量子密钥分发方法和介质
US20200009170A1 (en) 2016-09-13 2020-01-09 Megumi Tanaka Sleep display agent property and method for improving sleep disorders
ES2955713T3 (es) 2016-09-13 2023-12-05 Megumi Tanaka Agente de mejora de la función visual, y método para mejorar la función visual
CN120383644A (zh) 2016-11-11 2025-07-29 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成
CN110325190A (zh) 2016-12-21 2019-10-11 新南创新私人有限公司 增加血管密度的方法
CN106755209B (zh) 2016-12-29 2021-07-23 苏州汉酶生物技术有限公司 一种酶法制备β-烟酰胺单核苷酸的方法
EP3568488A4 (en) 2017-01-13 2020-09-23 The Regents of The University of Colorado, A Body Corporate METHODS OF TREATMENT OF HYPERTENSION AND ARTERIAL RIGIDITY
JP6974360B2 (ja) 2017-01-31 2021-12-01 オリエンタル酵母工業株式会社 多分化能性幹細胞増殖促進剤
JP6920071B2 (ja) 2017-02-16 2021-08-18 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ アディポネクチン分泌向上剤
JP7182289B2 (ja) 2017-04-05 2022-12-02 コーネル ユニヴァーシティー β－ニコチネートエステルヌクレオチドおよびその調製プロセス
WO2019023748A1 (en) 2017-07-31 2019-02-07 Newsouth Innovations Pty Limited METHODS FOR INCREASING FERTILITY
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20210388018A1 (en) 2018-10-01 2021-12-16 Cornell University Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof
MX2021006788A (es) 2018-12-10 2022-04-01 Chromadex Inc Formas cristalinas de los ribósidos de nicotinoílo y derivados de estos, y métodos de preparación de estas.
JP2022523864A (ja) 2019-03-22 2022-04-26 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドリボシドのリン誘導体を含む組成物及びニコチンアミドアデニンジヌクレオチドのモジュレーションのための方法
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
WO2021234009A1 (fr) 2020-05-20 2021-11-25 Nuvamid Sa Compositions cosmetiques anti-age comprenant du nmn
KR20240020716A (ko) 2021-05-27 2024-02-15 메트로 인터내셔널 바이오테크 엘엘씨 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
PRODUCT INFORMATION, Β-NICOTINAMIDE MONONUCLEOTIDE, ITEM NO.16411, [ONLINE], JPN7019003088, 11 March 2014 (2014-03-11), ISSN: 0004432462 *
SYNTHESIS, vol. 1981, no. 5, JPN6017038721, 1981, pages 388 - 389, ISSN: 0004432463 *
仲井由宣 花野学編, 新製剤学, vol. 第１版第２刷, JPN6016032041, 25 April 1984 (1984-04-25), pages 102 - 104, ISSN: 0004432464 *
塩路雄作, 固形製剤の製造技術, vol. 普及版第１刷, JPN6016031894, 27 January 2003 (2003-01-27), pages 9 - 14, ISSN: 0004432465 *
平山令明編著, 有機化合物結晶作製ハンドブック−原理とノウハウ−, JPN6016031902, 25 July 2008 (2008-07-25), pages 37 - 84, ISSN: 0004432466 *
社団法人日本化学会編, 第４版 実験化学講座１ 基本操作Ｉ, vol. 第２刷, JPN6016031896, 5 April 1996 (1996-04-05), pages 184 - 186, ISSN: 0004432467 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021192683A1 (enExample) * 2020-03-27 2021-09-30
WO2021192683A1 (ja) * 2020-03-27 2021-09-30 オリエンタル酵母工業株式会社 β－ニコチンアミドモノヌクレオチド又はその薬理学的に許容される塩からなる化合物、並びにその品質評価方法および酵素反応性の判定方法
JP7648026B2 (ja) 2020-03-27 2025-03-18 オリエンタル酵母工業株式会社 β－ニコチンアミドモノヌクレオチド又はその薬理学的に許容される塩からなる化合物を含む組成物、並びにその品質評価方法および酵素反応性の判定方法
JPWO2021200545A1 (enExample) * 2020-03-30 2021-10-07
JP7677949B2 (ja) 2020-03-30 2025-05-15 オリエンタル酵母工業株式会社 幹細胞の染色体安定化剤
JP2023001064A (ja) * 2021-06-18 2023-01-04 邦泰生物工程（深▲セン▼）有限公司 ニコチンアミドモノヌクレオチド共結晶を調製する方法
JP2023001065A (ja) * 2021-06-18 2023-01-04 邦泰生物工程（深▲セン▼）有限公司 ニコチンアミドモノヌクレオチド－イソニコチノイド共結晶およびその組成物
JP7394410B2 (ja) 2021-06-18 2023-12-08 邦泰生物工程（深▲セン▼）有限公司 ニコチンアミドモノヌクレオチド共結晶を調製する方法
JP7438512B2 (ja) 2021-06-18 2024-02-27 邦泰生物工程（深▲セン▼）有限公司 ニコチンアミドモノヌクレオチド－イソニコチノイド共結晶およびその組成物
WO2025004768A1 (ja) * 2023-06-29 2025-01-02 株式会社カネカ 結晶性複合体、及びその製造方法、並びに組成物

Also Published As

Publication number Publication date
CN108697722B (zh) 2021-03-23
US20190085009A1 (en) 2019-03-21
GB2542881A8 (en) 2017-05-10
CA3000744A1 (en) 2017-04-06
US20250171485A1 (en) 2025-05-29
MX390064B (es) 2025-03-20
CA3000744C (en) 2024-02-13
EP4272746A3 (en) 2023-11-15
US20180282362A1 (en) 2018-10-04
US12391721B2 (en) 2025-08-19
IL258276A (en) 2018-05-31
EP3355895A1 (en) 2018-08-08
ZA201802657B (en) 2024-02-28
AU2016331918B2 (en) 2021-11-04
KR20180073582A (ko) 2018-07-02
MX2018003656A (es) 2018-04-30
GB2542881A (en) 2017-04-05
EA037104B1 (ru) 2021-02-05
GB201608747D0 (en) 2016-06-29
EP4272746A2 (en) 2023-11-08
US10233208B1 (en) 2019-03-19
IL258276B (en) 2022-07-01
CN108697722A (zh) 2018-10-23
US11059847B2 (en) 2021-07-13
EP3355895A4 (en) 2019-03-13
GB2542881B (en) 2020-01-01
JP2021063081A (ja) 2021-04-22
US10392416B2 (en) 2019-08-27
US20220098229A1 (en) 2022-03-31
AU2016331918A1 (en) 2018-05-10
US20200157136A1 (en) 2020-05-21
JP2022176979A (ja) 2022-11-30
KR102779733B1 (ko) 2025-03-12
WO2017059249A1 (en) 2017-04-06
US20190225641A1 (en) 2019-07-25
BR112018006243A2 (pt) 2018-10-16
US10392415B2 (en) 2019-08-27
JP2024161353A (ja) 2024-11-19
EA201890817A1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
US12391721B2 (en) Crystal forms of beta-nicotinamide mononucleotide
US11180521B2 (en) Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN109640983A (zh) 醛捕获化合物和其用途
JP2018530524A (ja) アルデヒドコンジュゲートおよびその使用
CN102341380A (zh) 布美他尼、呋塞米、吡咯他尼、佐塞米和托拉塞米类似物、组合物和使用方法
CN110325179A (zh) 用于治疗慢性疼痛的组合物和方法
CN107428652A (zh) 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
US9012674B1 (en) Ethyl (2R)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof
BR112020009361A2 (pt) composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto
KR101414831B1 (ko) 모다피닐 또는 이의 유도체를 포함하는 ＫＣａ3.1 채널 매개 질환 치료용 조성물
HK40099497A (en) Crystal forms of beta-nicotinamide mononucleotide
CN117959301A (zh) 一种药物组合物、器官保存液及其应用
TW201400447A (zh) ３－（１５－羥基十五烷基）－２，４，４－三甲基－２－環己烯－１－酮之共結晶
CN110267661A (zh) 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐
EP4616853A1 (en) Lipo-hydroxamic acid derivative and pharmaceutical use thereof
JP2023509283A (ja) Ａｔｐ効率を向上するための相乗的栄養組成物
TW202124359A (zh) 用於增加磷酸化ampk蛋白含量之方法及材料

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181004

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201211

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201222

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210105

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210129

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210202

C27B Notice of submission of publications, etc. [third party observations]

Free format text: JAPANESE INTERMEDIATE CODE: C2714

Effective date: 20210914

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220517

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220628

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220726

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220726